Skip to main content
Home > Week in Review > Deals

Chronological Index of : Deals

 Current Issue
  • University of Oxford, Sequenom deal

    University of Oxford, Oxford, U.K. Sequenom Inc. (NASDAQ:SQNM), San Diego, Calif. Business: Diagnostic Sequenom purchased from the university's Isis Innovation Ltd. tech transfer arm IP covering noninvasive prenatal …

    Published on 10/20/2014
  • Agreen Biotech Co. Ltd. China, Cellular Biomedicine deal

    Agreen Biotech Co. Ltd. China, Cellular Biomedicine Group Inc. (NASDAQ:CBMG), Palo Alto, Calif. Business: Supply/Service, Cancer Cellular completed its acquisition of Chinese cancer supply/service company Agreen in a …

    Published on 10/13/2014
  • Anaptys, Momenta deal

    AnaptysBio Inc., San Diego, Calif. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Business: Autoimmune, Antibodies Momenta exercised an option to acquire worldwide rights to antibodies against an …

    Published on 10/13/2014
  • Ariad, Bellicum deal

    Ariad Pharmaceuticals Inc. (NASDAQ:ARIA), Cambridge, Mass. Bellicum Pharmaceuticals Inc., Houston, Texas Business: Gene/Cell therapy Ariad and Bellicum amended a 2006 deal granting Bellicum rights to use Ariad's cell-…

    Published on 10/13/2014
  • Auxilium, Endo deal

    Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), Chesterbrook, Pa. Endo International plc (NASDAQ:ENDP;TSX:ENL), Dublin, Ireland Business: Musculoskeletal, Genitourinary, Endocrine/Metabolic Endo won its bid to acquire …

    Published on 10/13/2014
  • BGI, Vancouver Prostate Centre (VPC) deal

    BGI, Shenzhen, China The Vancouver Prostate Centre (VPC), Vancouver, B.C. Business: Cancer BGI and VPC established the BGI-VPC Joint Research Laboratory to jointly discover and advance basic and translational cancer …

    Published on 10/13/2014
  • BioHealth Innovation, Roche deal

    BioHealth Innovation Inc., Rockville, Md. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pharmaceuticals BioHealth will identify health technologies from academic institutions, federal laboratories and …

    Published on 10/13/2014
  • Bristol-Myers, University of Texas MD Anderson Cancer Center deal

    Bristol-Myers Squibb Co. (NYSE:BMY), New York, N.Y. University of Texas MD Anderson Cancer Center, Houston, Texas Business: Cancer Bristol-Myers partnered with the center to evaluate the pharma's Opdivo nivolumab, …

    Published on 10/13/2014
  • CleveXel Pharma, Shanghai Fosun Pharmaceutical deal

    CleveXel Pharma S.A.S., Maisons-Alfort, France Shanghai Fosun Pharmaceutical Group Co. Ltd. (Shanghai:600196;HKSE:2196), Shanghai, China Business: Infectious CleveXel and Fosun's Guilin Pharmaceutical Co. Ltd. partnered…

    Published on 10/13/2014
  • Durata Therapeutics, Actavis deal

    Durata Therapeutics Inc. (NASDAQ:DRTX), Chicago, Ill. Actavis Group, Zug, Switzerland Business: Infectious Actavis will acquire Durata for $23 per share in cash up front, or $675 million, plus up to $146.5 million in …

    Published on 10/13/2014
  • InnoPharma, Pfizer deal

    InnoPharma Inc., Piscataway, N.J. Pfizer Inc. (NYSE:PFE), New York, N.Y. Business: Drug delivery, Generics Pfizer completed its acquisition of sterile injectable company InnoPharma for $225 million in cash up front. …

    Published on 10/13/2014
  • InterMune, Roche deal

    InterMune Inc., Brisbane, Calif. Roche (SIX:ROG;OTCQX:RHHBY), Basel, Switzerland Business: Pulmonary Roche completed its acquisition of InterMune for $74 per share, or $8.3 billion in cash (see BioCentury, Sept. 1).

    Published on 10/13/2014
  • JenKem, 3SBio deal

    JenKem Technology Co. Ltd., Beijing, China 3SBio Inc., Shenyang, China Business: Cancer JenKem granted 3SBio exclusive rights in China to develop and commercialize PEG-irinotecan, a long-acting polymer-drug conjugate …

    Published on 10/13/2014
  • London Health Sciences Centre, Novare deal

    London Health Sciences Centre, London, Ontario Novare Pharmaceuticals, Boston, Mass. Business: Autoimmune, Dermatology, Pulmonary London Health Sciences Centre granted newco Novare rights to therapeutic products that …

    Published on 10/13/2014
  • Mayo Clinic, Cardio3 BioSciences deal

    Mayo Clinic, Rochester, Minn. Cardio3 BioSciences S.A. (Euronext:CARD), Mont-Saint-Guibert, Belgium Business: Gene/Cell therapy The Mayo Clinic and Cardio3 expanded a 2007 deal granting Cardio3 exclusive rights to the …

    Published on 10/13/2014
  • PharmEste, Ario Pharma deal

    PharmEste, Bresso, Italy Ario Pharma Ltd., Cambridge, U.K. Business: Inflammation Ario acquired transient receptor potential A1 (TrpA1) antagonist assets previously owned by PharmEste. The assets include a series of …

    Published on 10/13/2014
  • Progenics, Salix deal

    Progenics Pharmaceuticals Inc. (NASDAQ:PGNX), Tarrytown, N.Y. Salix Pharmaceuticals Ltd. (NASDAQ:SLXP), Raleigh, N.C. Business: Neurology Progenics received a $40 million milestone payment from Salix under a 2011 deal …

    Published on 10/13/2014
  • QLT, Auxilium deal

    QLT Inc. (TSX:QLT;NASDAQ:QLTI), Vancouver, B.C. Auxilium Pharmaceuticals Inc. (NASDAQ:AUXL), Chesterbrook, Pa. Business: Ophthalmic Auxilium backed out of its previously announced deal to merge with QLT in a stock deal …

    Published on 10/13/2014
  • Sanofi, University of Florida deal

    Sanofi (Euronext:SAN;NYSE:SNY), Paris, France University of Florida, Gainesville, Business: Ophthalmic Over three years, Sanofi's Genzyme Corp. unit will provide a $900,000 grant to a researcher at the University of …

    Published on 10/13/2014
  • Shionogi, AstraZeneca deal

    Shionogi & Co. Ltd. (Tokyo:4507), Osaka, Japan AstraZeneca plc (LSE:AZN;NYSE:AZN), London, U.K. Business: Cardiovascular Shionogi granted AstraZeneca's MedImmune LLC unit exclusive, worldwide rights to develop and …

    Published on 10/13/2014
  • XenoBiotic Laboratories, WuXi PharmaTech deal

    XenoBiotic Laboratories Inc., Plainsboro, N.J. WuXi PharmaTech Inc. (NYSE:WX), Shanghai, China Business: Supply/Service WuXi acquired CRO XenoBiotic, which provides bioanalytical, drug metabolism and pharmacokinetic …

    Published on 10/13/2014
  • Alios, J&J deal

    Alios BioPharma Inc., South San Francisco, Calif. Johnson & Johnson (NYSE:JNJ), New Brunswick, N.J. Business: Infectious Johnson & Johnson is acquiring Alios for about $1.8 billion in cash. The pharma receives Alios' …

    Published on 10/6/2014
  • Ambit, Daiichi Sankyo deal

    Ambit Biosciences Corp. (NASDAQ:AMBI), San Diego, Calif. Daiichi Sankyo Co. Ltd. (Tokyo:4568), Tokyo, Japan Business: Cancer Daiichi Sankyo will acquire Ambit Biosciences for up to $19.50 per share, or about $415 …

    Published on 10/6/2014
  • BioProtein, Pharming deal

    BioProtein Technologies S.A., Jouy-en-Josas, France Pharming Group N.V. (Euronext:PHARM), Leiden, the Netherlands Business: Hematology, Endocrine/Metabolic Pharming acquired assets from contract manufacturing …

    Published on 10/6/2014
  • Compugen, Baize deal

    Compugen Ltd. (NASDAQ:CGEN;Tel Aviv:CGEN), Tel Aviv, Israel Baize Investments Ltd., Tel Aviv, Israel Business: Autoimmune, Cancer Compugen reacquired Baize's stakes in mAbs against undisclosed cancer targets discovered …

    Published on 10/6/2014

< Previous   1  2  3  4  5  6  Next >
Subscribe Now
Free Trial

About BioCentury

Decision-shaping business intelligence for the global biotech and pharma industry since 1993